Arterial hypertension and cardiovascular risk: Need for a combined strategy of intervention;Ipertensione arteriosa e rischio cardiovascolare globale: Necessità di una strategia d'intervento combinata

Clinica Terapeutica

Volumn 159, Issue 4, 2008, Pages 269-273

  Paoletti, V ^a   Raparelli, V ^a   Ferroni, P ^b   Scarno, A ^a   Trinchieri, F ^a   Basili, Stefania ^a,d   Davi G ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

Angiotensin II; Arterial hypertension; Cardiovascular risk; Endothelial dysfunction; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ATORVASTATIN; SIMVASTATIN;

BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PATHOGENICITY; REVIEW;

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; METABOLIC SYNDROME X; MYOCARDIAL ISCHEMIA; OXIDATIVE STRESS; RISK;

EID: 51849112804     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Zanchetti A, Hansson L, Dahlof B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens 2001; 19:1149-59
2. Peeters A, Mamun AA, Willekens F, et al. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23:458-66
3. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-4
4. Pepine CJ, Handberg EM. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. Clin Cardiol 2001; 24:V1-V5
5. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37:1047-52
6. Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106:2800-5
7. Minuz P, Patrignani P, Gaino S, et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43:64-70
8. Corseaux D, Olliver V, Fontaine V, et al. Hemostasis imbalance in experimental hypertension. Mol Med 2002; 8:169-78
9. Levi M, Van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109:2698-704
10. Ramesh KV, Ashok Shenoy K. Endothelial dysfunction: many ways to correct-trends that promise. Indian J Pharmacol 2003; 35:73-82
11. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21:1145-51
12. Taddei S, Virdis A, Mattei P, et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20:S193-5
13. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab 2002; 13:364-8
14. Racasan S, Braam B, Koomans HA, et al. Programming blood pressure in SHR by shifting the perinatal balance of NO and reactive oxygen species towards NO: the inverted Barker phenomenon. Am J Physiol Renal Physiol 2005; 288:F626-36
15. Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100:2131-4
16. Yusuf S, Sleight P, Pouge J, et al. Effects of an angiotensin- converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53
17. Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-Converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35:353-9
18. Yavuz B, Ilker YM, Turgay C, et al. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens 2003; 21:1207-11
19. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16:123-8
20. Kobayashi N, Mita S, Yoshida K, et al. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-kB induced by oxidative stress. Hypertension 2003; 42:1004-13
21. Schriffin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and endothelial function. J Hypertens 2002; 20;71-8
22. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-76
23. Jukema JW, Zwinderman AH, van Boven AJ, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The Regress Study Group. Arterioscler Thromb Vasc Biol 1996; 16:425-30
24. Heart Protection Study Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22
25. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-then-average cholesterol concentrations in the Anglo Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled Trial. Lancet 2003; 361:1149-58
26. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419-23
27. Kingwell BA. Nitric oxide as a metabolic regulator during exercise: effects of training in health and disease. Clin Exp Pharmacol Physiol 2000; 27:239-50